Peritonitis Clinical Trial
Official title:
Phase 4 Study of Primary Use of the Vacuum Assisted Laparostomy in Treatment of Severe Peritonitis
The aim of the project was to optimalize the process in severe peritonitis which is generally inflicted with high mortality and morbidity with long term costly therapy. Therapy of severe intraabdominal infection consist of treatment of the infection site and following closure of the abdominal cavity with possibility of re-laparotomy and in treatment of complications when needed; or closure introduction of laparostomy with intention to control complications prevention however with risk of tertiary peritonitis. Modern process is laparostomy with active suction (VAC) method which reduces the risk of tertiary peritonitis. It efficacy is however approved especially in therapy of complications. Based on the investigators experiences the investigators use this method even in case of primary treatment of severe peritonitis which led to protocol processing (VAC in case of primary closure of the abdominal cavity; VAC exchange according to scoring system; secondary closure of the abdominal cavity or early coverage with collagen mesh). The aim of this project is to prove reduced mortality, morbidity and hospitalization length (cost reduction) in prospective randomized study in patients treated due to severe peritonitis using VAC method in comparison to classical approach (primary closure of the abdominal cavity; secondary solution of complications).
Introduction Severe peritonitis belongs among severe diseases with mortality 20-60%. Causes
are number of primary surgical diseases (inflammatory acute abdomen syndromes - perforated
diverticulitis, perforated tumor, colon ischemia and other) or complications after abdominal
surgeries in frequency 12-16%.
Secondary and tertiary peritonitis can be in insult causing system inflammatory response
(SIRS) with subsequent sepsis and multi-organ failure; it is serious state of patient who
requires long term and costly intensive care and despite of that it often ends with
permanent disability. Basic therapy of severe peritonitis is surgical treatment of origin of
abdominal sepsis, contamination elimination and prevention of postoperative complications.
The insufficient capability to manage postoperative complications (polymorbidity, diabetes,
inveterate peritonitis, immunosuppressed patient) is often the cause of organ and
mutli-organ failure. In case of primary closure of the abdominal cavity and after correct
surgical treatment; solution is the early diagnosis of the complications and their urgent
sanitation. Mostly from objective reasons there is delay in complication diagnosis and thus
adequate treatment. Other negative consequence of primary closure of the abdominal cavity in
case of development of intraabdominal complicated healing is the development of
intraabaominal hypertension and even compartment syndrome with all negative influences to
organ functions. Alternative is to introduce laparostomy which enables simple abdominal
cavity control (second look method) using repeated interventions. Classical laparostomy is
however continual continuation of the tertiary contamination. According to known literal
sources there is no recommendation for means of abdominal cavity closure in the above given
surgical disease which is therapeutically more efficient.
One of the modern laparostomy methods is closure of the abdominal cavity using VAC. Method
principle is the active suction which is continual and it drains effusion from the abdominal
cavity and thus reduces intraabdominal bacterial contamination and also supports blood
circulation and vitality of the wound edges. It is a method which fulfills advantages of
laparotomy including expansion of the abdominal cavity, effusion drainage quality of which
can be controlled; it is a closed system in which there is no risk of external contamination
as in case of common laparostomy. Use of VAC method was verified in various wound types with
copious secretion (sternotomy, diabetic foot or fascitis). Method of VAC laparostomy was
described; however prospective and randomized use in peritonitis has not bee evaluated yet.
Aim of the project: The aim of this project is to prove reduced mortality, morbidity and
hospitalization length (cost reduction) in prospective randomized study in patients treated
due to severe peritonitis using VAC method in comparison to classical approach (primary
closure of the abdominal cavity; secondary solution of complications). Secondary aim is to
validate scoring systems and early sepsis markers (cytokines) in algorithm of assessment of
severance of severe peritonitis in our conditions and their inclusion in indication for
surgical revision. Tertiary aim is to determine group of patient who would profit the most
from the method.
Further aim is to compare costs and socio-economic implications of both therapy options.
Hypothesis: Primary introduction for surgical revision due to severe peritonitis reduces
postoperative morbidity and mortality in comparison with primary closure of the abdominal
cavity.
Indications for repeated intervention improves combination of scoring systems and
immunohistochemistry markers.
Methodology
1- assessment of preoperative stave of patient - APACHE II (Acute Physiology and Chronic
Health Evaluation, ASA, BMI), severity of clinical and surgical finding.
2 - Assessment of influence of selected method primary treatment of the abdominal cavity on
the postoperative morbidity which is expressed by monitoring basic vital functions, SOFA
(Sequential Organ Failure Assessment), intraabdominal pressure monitoring, serum level of
cytokines monitoring, postoperative complications, surgical revision and length of
hospitalization.
3 - long term and socioeconomic consequence (30 days of follow up after discharge -
questionnaire, assessment of life quality), cost analysis expended for hospitalization
including medication, surgery as well as postoperative outpatient control visits.
Patient with severe peritonitis will be enrolled in study according to Mannheim Peritonitis
Index (MPI) - more than 20-25 according to sex; APACHE II more than 10. Expected sample size
is total of 50 patients (25 treated using VAC method) versus 25 in control group). Screening
will include all patients designer fulfilling SIRS criteria prior abdominal approach and/or
displaying symptoms of peritonitis. If patient fulfills these criteria and agrees with
inclusion in study, his/her ID is entered in the electronic database which generates
inclusion in one out of two groups according randomization scheme - surgery termination
using VAC method or primary suture. Excluded patients: young patients younger than 18 years;
mental state of patients which does not enable proper information and signature of informed
consent form (see bellow) with inclusion in study; further patients who cannot be assume to
live longer than 48 hours after surgery (APACHE II, Karnofski, SOFA).
Preoperative care and actual surgical procedure is not the direct subject of study and will
be conducted according to so far known procedures. Surgeon will closed the abdominal cavity
according randomization at the end of procedure and this fact is in no way affected by
actual surgery procedure.
Patient will be treated at the surgical ICU. First exchange of VAC dressing will be
conducted after 24-48 hours and subsequently so called on demand (patient health state
aggravation defined as score SOFA increase by 4 and more points; elevation of inflammatory
markers and interleukins). After complete sanitation of the origin the investigators close
the laparostomy (only serous exudate) If it is not technically possible to suture abdominal
cavity according to layers, the investigators will close it using following alternatives:
single skin cover, mesh plasty, covering with celless skin implant (permacol surgical
implant) so the abdominal cavity was closed as soon as possible.
Patient with primary closed abdominal cavity (control group) will be treated according to so
far known procedure. In case of inflammation signs the investigators will search and treat
this focus. Cytokine inflammatory markers will be also monitored and including finding. In
case of surgical complication the investigators will proceed in standard manner (SSI). VAC
method will not be used in cases of those patients.
Hospitalization will be terminated after criteria compliance which are: oral intake higher
than 2 liters tolerance; sufficient oral analgesics; patient does not display infection
signs; agrees with hospitalization; surgical wound is treatable in outpatient clinic.
Means of data collection
Preoperative examination will monitor apart from basic data such as age, diagnosis,
co-morbidity score ASA, BMI, level of inflammatory parameters (CRP, blood count, other
biochemistry examination). Patient must fulfill criteria SIRS to be enrolled in the study
and display signs of peritonitis. Precise indication to surgery will be recorded. After
introduction of anesthesia the investigators will perform examination of arterial blood
(ASTRUP) and will calculate APACHE
Extent of inflammation (MPI) will be evaluated and source of infection (confirmation or
exclusion of preoperative diagnosis). Performed surgical procedure will be described, the
investigators will monitor duration of surgery; blood loss; monitoring whether sufficient
control of primary source (insufficient treatment of source is sufficient exclusion
criterion).
Daily the investigators will monitor IL-1, 6, 8, 10 and TNF alpha while at ICU (during first
5 days), SOFA score will be calculated and IAP will be measured. The investigators will
further monitor frequency of VAC exchanges; number of administrated transfusions; duration
of UPV; days without oral intake and without possibility of physiotherapy - walking
(parameters of recovery. Conscious patients will be submitted form for assessment of life
quality (SF-36) on the 7th postoperative day. The investigators will further monitor pain
using VAS.
Entry values are: hospitalization length, number of ICU days; mean of wound closure (primary
suture, delayed suture after VAC; skin cover and other). Incidence and severity of SSI
(I-III grade) and further nosocomial infection (health care - associated infection - HAI).
Patient again completes from assessing life quality (SF-36) prior discharge. Active follow
up will be in terms of study conducted via telephone every 30th day after discharge. Patient
will subsequently complete mailed questionnaire with assessing life quality (SF-36).
Outpatient controls will be necessary and repeated hospitalization in complicated patients.
After completion of patient monitoring the analysis of cost for hospitalization including
medication, surgery and postoperative outpatient control will be conducted using the
hospital information system.
Statistical processing
Sample size is estimated based on expected percentage indicator according to Fleisse. Other
sample size estimates were estimated using standard method. Each sample must contain 26 -47
patients for mortality estimated between 30-40% and in case of statistically significant
difference 20-30% when 5% level of significance and test power 70% in case of one sided
test. Morbidity estimated to 60% and clinically significant difference 30-40% requires
sample size of 19-32 subjects providing the same significance level and one sided test.
Statistical evaluation of results will be included based on pair tests. Difference of
individual variables between both groups will be evaluated using Student pair test or its
non-parametric variant (Wilcoxon test). SOFA, APACHE II scores and life quality assessment
results (SF-36) will be evaluated using Hotelling test as multi directional generalization
of Student test.
Time schedule:
1. year of the project: design of randomization program; personal education with study
protocol; software design; inclusion of 18 patients. Data processing. Results will be
evaluated at the end of the year; statistician will evaluate homogeneity of groups.
2. year of the project: inclusion of further 18 patients. Data analysis will be performed
and subgroup analysis and partial results will be processed and presented.
3. year of the project: inclusion of the last 14 patients. Follow up termination. Definite
data collection, analysis, results evaluation including financial analysis. Standard
proposal. Presentation in national and international forums, publications.
Discussion Surgical treatment is inseparable part of patient care with severe peritonitis.
Advance monitoring is important for identification of risk patients but also for possible
surgical revision indication. Generally used sepsis markers including scoring systems
(APACHE II, MOSF - Multiple Organ System Failure, MODS - Multiple Organ Dysfunction Score)
however react with certain delay. Possible or on demand re-laparotomy is performed
afterwards in patient in severe conditions with MODS. On the other hand planned
re-laparotomies are conducted excessively. Not even met-analysis of clinical studies proved
clear preference of one procedure (23). New method VAC however has not been evaluated in
prospective randomized study in this indication. Inclusion of early markers of septic state
- IL-1, 6, 8, 10 a TNF alpha - in indication for re-laparotomy or VAC exchange could have
large clinical benefit. Further controversial indication parameter commonly measured at ICU
is size and development of IAP which can present important correlation with laboratory signs
of inflammation and it can lead for design of special index. VAC method use has its
advantages - active and closed intraabdominal secretion restricts possibilities of spreading
HAI. Significant and reduced frequency of dressing; enables simple physiotherapy of
patients; condition of anabolic phase which is necessary for any healing (24). Analysis of
patient number which benefit from this method (intention-to treat) against general costs is
necessary.
Designer's working site has treated 19 patients over the last 18 months using this method.
Mortality was 15.8% and average hospitalization length 59.2 days which is in compliance of
so far published results. However it has not been prospective randomized study and VAC
method was however used as the last therapeutic option.
Information Working site has needed surgical equipment including equipment for performing of
VAC; VAC is used as method for 5 years; apart from purchase of consumption material he is
the only owner of the pump. This method has been used to treat different wounds. Principal
investigator and all co-workers has experience with this method. Co-investigator has even
numerous experiences with clinical studies and he published his results in journals. Other
specific equipment is not necessary for study procedure.
Conclusion Detected results will background for verification of efficacy of VAC introduction
into laparostomy in patients after surgical revision due to severe peritonitis. Efficacy of
new and standard laboratory and clinical markers of septic state.
Expected results, aims, priorities and significance of the project Study output will consist
of data usable for design of recommended procedure for surgical patient care with severe
peritonitis. Standardized protocol will be introduced for ICU patients which reflect only
those laboratory methods and clinical parameters which clinically influence therapy.
Detailed analysis for both groups will enable precise indication single surgical
interventions which will ensure efficient and thus cost wise preferable therapy. Simple
universal software will be created in terms of study which manages patient database and thus
enables rapid concurrent assessment of health care quality.
With regard that similar complex prospective study has not been published in national and
international magazines, publication in impact journal; socioeconomic analysis will be
published especially in national medical journals so it would be easily accessible.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04070196 -
Point-of-care Test for Diagnosis of Peritonitis in Peritoneal Dialysis Patients
|
N/A | |
Completed |
NCT00657566 -
SIS Multicenter Study of Duration of Antibiotics for Intraabdominal Infection
|
Phase 3 | |
Recruiting |
NCT00131196 -
Functional Genomic Influences on Disease Progression and Outcome in Sepsis
|
N/A | |
Completed |
NCT00195351 -
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection
|
Phase 4 | |
Completed |
NCT04182217 -
Descriptive and Correlational Study of Peritonitis in Haiti.
|
||
Recruiting |
NCT03310606 -
Serum and Peritoneal Concentration in Antibiotics During the Surgical Management of Peritonitis
|
N/A | |
Completed |
NCT01222663 -
Effects of Hemoperfusion With a Polymyxin B Membrane in Peritonitis With Septic Shock
|
Phase 3 | |
Completed |
NCT00230971 -
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)
|
Phase 4 | |
Recruiting |
NCT03790176 -
ZAVI APD ELF Protocol v2.2
|
Phase 1 | |
Completed |
NCT03668197 -
Children Peritonitis Ecology at CHU de Rennes - (IIAPEDIA)
|
||
Recruiting |
NCT01837342 -
Multicenter Study Comparing Morbidity and Quality of Life Associated in the Treatment by Surgical Resection and the Conservative Treatment, After Favorable Evolution of Purulent Peritonitis That Originates From Diverticulitis Treated by Mini-invasive Surgery
|
N/A | |
Completed |
NCT00497744 -
A Pharmacokinetic Study of Cefepime After Administration Into Dialysate in Patients With Continuous Ambulatory Peritoneal Dialysis (CAPD) Peritonitis
|
N/A | |
Recruiting |
NCT03334006 -
Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis (PEPPER Trial).
|
Phase 2 | |
Terminated |
NCT03403751 -
Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury
|
Phase 3 | |
Withdrawn |
NCT00463762 -
Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.
|
Phase 4 | |
Active, not recruiting |
NCT02755610 -
Check List to Improve Patient Self-care and Product Defect Report in Continuous Ambulatory Peritoneal Dialysis
|
N/A | |
Not yet recruiting |
NCT05308849 -
Peritoneal Diffusion and Efficacy of Antibiotic Therapy in Pediatric Peritonitis
|
N/A | |
Completed |
NCT02726932 -
Intra-abdominal View and Inflammatory Markers in Secondary Peritonitis - Correlation to Recovery
|
||
Recruiting |
NCT05050253 -
Lavage With Super-Oxidized Solution for Secondary Peritonitis
|
N/A | |
Completed |
NCT02926846 -
IV Antibiotics With Lavage for Severe PD Peritonitis
|
Phase 4 |